Sector portfolio · Hedge fund
Arch's Biotech portfolio
Arch has backed 18 Biotech startups in rounds we track, $3.5B between them, shown by the stage each has reached. The best-funded is Erasca.
Funding by segment
- Series B$1.5B6
- Series C and later$746M6
- Series A$982M4
- Stage not reported$275M2
Where they are based
- United States15$2.7B
- China3$734M
United States
ChinaFounded
7 without a founding year on record.
Total raised
- Under $1M0
- $1M to $10M0
- $10M to $50M5
- $50M to $250M8
- $250M to $1B5
- $1B and over0
Each dot is a startup: the year it was founded across, the total it has raised up (each line is ten times the one below). Pick a segment to pick it out.
11 of 18 startups shown; the rest have no founding year or amount on record.
- 1 to 2
- 3 to 7
- 8 to 24
- 25 to 99
- 100 and more
- United States15
- China3
Startups by country, 2 countries in all.
Segment by segment
Series B
6 startups · $1.5B raised
Gossamer BioGossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.United States$567M- CCStoneChina$410M
Beam TherapeuticsBeam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.United States$322M- JBJust BiotherapeuticsChina$64M
OmniomeOmniome engages in developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy.United States$60M- CCytrellisUnited States$29M
Series C and later
6 startups · $746M raised
LifeMine TherapeuticsLifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines.United States$230M
908 Devices908devices manufactures battery-operated, hand-held chemical detection tools used in mass spectrometry.United States$168M
KSQ TherapeuticsKSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.United States$156M- CCodiakUnited States$77M
ImmusanTImmusanT develops therapeutic vaccines for the treatment of celiac disease.United States$72M
OncoResponseOncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.United States$44M
Series A
4 startups · $982M raised
ErascaErasca is a developer of oncology drugs intended to provide precision oncology options.United States$739M
Verve TherapeuticsVerve Therapeutics is a genetic medicine firm that is developing treatments for cardiovascular disease.United States$202M- MNMagnolia NeuroscienceUnited States$31M
- BBoragenUnited States$10M
Stage not reported
2 startups · $275M raised
- BBBrii BioChina$260M
- RTRodeo TherapeuticsRodeo Therapeutics is a developer of small-molecule therapies designed to promote regeneration and repair of multiple tissue types.United States$15M
How this map is made. Every startup here works in Biotech and has raised money in a round we track that names Arch as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.
More portfolio maps
All portfoliosRaising from investors like Arch?
Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.